Advanced Course in Immunology On Demand Lecture Recordings-Engineering T Cell Immunity

Video Transcription

Video Summary

The speaker traced the history and future of T-cell immunotherapy, especially CAR T-cell therapy, as a way to engineer immunity against cancer and other diseases. The story began with allogeneic bone marrow transplantation, where donor T cells were discovered to attack leukemia in recipients—a beneficial “graft-versus-leukemia” effect—but also caused harmful graft-versus-host disease. This duality inspired the goal of separating anti-cancer immunity from toxicity.<br /><br />He then described the development of tumor-infiltrating lymphocytes and, later, chimeric antigen receptors (CARs), which combine antibody-based antigen recognition with T-cell activation signals. Second-generation CARs, which include costimulatory domains, proved effective, while earlier and more complex versions often failed. The breakthrough target was CD19, a B-cell marker, leading to dramatic remissions in refractory leukemia and lymphoma, especially in children like Emily Whitehead. This culminated in FDA approval of the first engineered cell therapy, Kymriah.<br /><br />However, the talk emphasized that CAR T-cell therapy is not a universal cure. Many patients relapse due to antigen escape, T-cell exhaustion, or the hostile environment of solid tumors. Solid tumor applications are emerging slowly, with early promise in glioblastoma, neuroblastoma, and DIPG. The speaker also highlighted expanding uses beyond cancer, including autoimmune disease, heart failure fibrosis, and even Alzheimer’s disease in preclinical models.<br /><br />Finally, he discussed major challenges: cytokine release syndrome, neurotoxicity, high cost, limited access, and manufacturing hurdles. The future, he argued, lies in smarter engineering—better targets, better receptors, gene editing, and more scalable, equitable delivery systems.

Asset Subtitle

Lecture 20: Nathan Singh, Washington University School of Medicine

Engineering T Cell Immunity

Asset Caption

Nathan Singh, Washington University School of Medicine
Engineering T Cell Immunity

Keywords

T-cell immunotherapy

CAR T-cell therapy

graft-versus-leukemia

graft-versus-host disease

chimeric antigen receptors

CD19

Kymriah

antigen escape

cytokine release syndrome

solid tumors

gene editing